Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Nordisk and Neose Technologies have announced that Novo Nordisk has completed the initial Phase I clinical trial with NN7128, a long-acting version of NovoSeven Coagulation Factor FVIIa administered intravenously.
Subscribe to our email newsletter
The trial assessed the safety and pharmacokinetics of NN7128 in 30 healthy subjects. In the trial a significant prolongation of the half-life of NN7128 was observed. Furthermore, single doses of NN7128 were well tolerated with no serious adverse events.
George Vergis, Neose president and CEO, said: “We are encouraged by the safety and pharmacokinetic profile that NN7128 has demonstrated in this Phase I study. We look forward to continued progress in the clinical development of this compound.”